NEW YORK – Immunocore ta ce a ranar Litinin za ta sayar da hannun jari 3,733,333 a cikin yarjejeniyar zuba jari ta hannun jari masu zaman kansu (PIPE) wanda ake sa ran zai tara dala miliyan 140.
A ƙarƙashin yarjejeniyar, Immunocore za ta sayar da hannun jarinta na gama gari da kuma hannun jarin da ba na gama gari ba kan dala $37.50 a kowace hannun jari. Masu zuba jari na kamfanin da ke cikin wannan harkar sun haɗa da RTW Investments, Rock Springs Capital da General Atlantic. Ana sa ran yarjejeniyar PIPE za ta ƙare a ranar 20 ga Yuli.
Kamfanin zai yi amfani da kuɗin da aka samu wajen samar da kuɗaɗen da za a yi amfani da su wajen samar da kuɗaɗen da za su taimaka wa masu fama da cutar kansa da kuma waɗanda ke yaɗuwa, ciki har da haɓaka babban ɗan takarar cutar kansa, Kimmtrak (tebentafusp-tebn), don magance cutar HLA-A*02:01 mai kama da fata da kuma cutar melanoma ta uveal. Ana sa ran kuɗaɗen, tare da kuɗaɗen shiga daga Kimmtrak, za su samar da kuɗaɗen ayyukan Immunocore har zuwa shekarar 2025.
A wannan shekarar, an amince da amfani da Kimmtrak ga marasa lafiya da ke dauke da cutar HLA-A*02:01 wadda ba a iya cirewa ko kuma wadda ta bazu a cikin uveal melanoma a Amurka, Turai da Birtaniya, da sauran ƙasashe. Immunocore ta ci gaba da nazarin maganin a wani bincike na Phase I/II a kan cutar HLA-A*02:01-positive.
Immunocore kuma tana haɓaka wasu ƙwararrun masu binciken cutar kansa guda huɗu, gami da ƙarin magungunan masu karɓar ƙwayoyin T guda biyu a cikin gwaje-gwajen Phase I/II a cikin ciwace-ciwacen da suka ci gaba. Ana haɓaka ɗayan magungunan don marasa lafiya da ke da HLA-A*02:01-positive da MAGE-A4-positive, ɗayan kuma yana kai hari ga ciwace-ciwacen HLA-A*02:01 da PRAME-positive. Kamfanin yana kuma da 'yan takara biyu da ba a bayyana sunayensu ba a cikin ci gaban cutar kansa kafin a fara aikin asibiti.
Dokar Sirri. sharuɗɗa da ƙa'idodi.Haƙƙin mallaka © 2022 GenomeWeb, wani ɓangaren kasuwanci na Crain Communications. an kiyaye duk haƙƙoƙi.